Navigation Links
AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
Date:9/10/2012

LONDON and CAMBRIDGE, Mass., Sept. 10, 2012 /PRNewswire/ -- AstraZeneca and the Broad Institute in Cambridge, Massachusetts today announce a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs.

Bacterial and viral infections remain a significant global health concern; according to the World Health Organisation's 'Global Burden of Disease' report, infectious and parasitic diseases are the world's second-largest leading cause of death and disability, and the growth of antibiotic-resistant "superbugs" that evade existing treatments is on the rise[1]. However, few pharmaceutical companies are conducting research in this area. Only two new classes of antibiotics have been introduced to the market in the past 30 years.

While the medical need to treat severe infections remains very high, the identification of high-quality lead compounds for drug development is a significant challenge. Under the two-year collaboration announced today, the two organizations will work together to address this challenge by bringing together deep expertise in bacterial genomics and biochemistry with a unique collection (or "library") of chemical compounds and chemical screening capabilities.

The chemical library, created at the Broad Institute, comprises 100,000 customized molecules known as Diversity-Oriented Synthesis (DOS) compounds. It is designed to contain molecular shapes and structures not found anywhere else that can hit even the most challenging biological targets. Under the agreement, screening and hit-to-lead chemistry will take place in the Broad's Chemical Biology Platform and AstraZeneca will optimize, develop and commercialize potential compounds from identified, high-quality leads.

Dr. Michael Foley, director of the Broad Institute's Chemical Biology Platform said: "We are thrilled to be working together with AstraZeneca on this project, which is closely aligned with the Broad Institute's mission to propel the understanding and treatment of human disease. The Broad is one of the few places that has made a meaningful investment in new chemistry in the last five years, and we welcome this remarkable opportunity to harness that investment to improve human health."

Dr. Manos Perros, vice president and head of the AstraZeneca Infection Innovative Medicines Unit said: "We believe new and collaborative approaches between the private and public sectors will help speed the discovery and development of new treatments, particularly for antibiotic-resistant infections. We are very pleased to work hand in hand with the Broad Institute to combine our unique resources and strong histories in innovation, discovery and development to speed advancements in treatments for infections. Through this collaboration we have already identified several new potential projects to pursue."

NOTES TO EDITORS

About AstraZeneca  ̶  Infection

The steady rise of drug-resistant bacteria is an imminent and urgent threat to public health. Diseases such as tuberculosis are huge health challenges in the developing world and a re-emerging health issue in many developed countries. As one of the leading companies still actively investing in novel antibiotic research, AstraZeneca remains steadfast in our commitment to discovering and developing new medicines to treat these diseases. With one of the world's largest antibacterial pipelines and strong partnerships, we focus on the development of treatments for serious bacterial infections, viral infections and diseases of the developing world as well as diagnostics and the development of novel vaccines. For more information, visit www.astrazeneca.com/research.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

About the Broad Institute of MIT and Harvard

The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.

Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to www.broadinstitute.org.

[1] http://www.who.int/mediacentre/factsheets/fs194/en/


'/>"/>
SOURCE AstraZeneca
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. Broad Patent Protection Granted for iBio Immunomodulator
9. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
10. Polish Medicine Attracts Patients From Abroad - Not Only During EURO 2012
11. The Biomedical Device Industry in America: Challenges at Home and Abroad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 More ... a further effort to help spread lessons learned from ... the International Diabetes Federation (IDF) and Eli Lilly and ... for the second phase of the Bringing Research in ... reaffirming their commitment to helping people with diabetes effectively ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root NPI Graph today ... a new, greatly improved version of the Doctor Referral teaming dataset commonly available from ... and subsequently called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic ... Erie Bayfront and Erie Convention Center on June 8-10. The weekend consisted ... quiz bowl, award and scholarship presentations, and professional networking. , On Friday ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids ... risk of visual loss in these patients. , But how often do ophthalmologists and ... cessation to patients at risk of or with early symptoms of AMD? A ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
Breaking Medicine News(10 mins):